Fresenius Snaps Up Remaining 45% of mAbxience for Up to €750M

• Fresenius acquired the remaining 45% of mAbxience for up to €750 million, completing the purchase on 30 September 2026 without requiring regulatory approval.
• The deal gives Fresenius full ownership of a vertically integrated biopharma business spanning research, development, manufacturing and commercialization.
• Full ownership increases Fresenius’ control over investment, production capacity and strategic decisions, and supports its #FutureFresenius strategy.
• The biosimilars market is expected to grow to more than €180 billion by 2035; mAbxience has four marketed products and eight candidates in development.
• The acquisition is expected to immediately increase Group core earnings per share. It will be funded from available liquidity and operating cash flow, with no new financing required.
• mAbxience generated more than €320 million in revenue in 2025 and employs over 1,300 people; Fresenius left its 2026 guidance and 2030 Biopharma ambition unchanged.

The next important date, Publication of quarterly financial report (as of Q3) Alternative: Release of quarterly financial report (cut-off date: Q3), at Fresenius is on 04.11.2026.

The price of Fresenius at the time of the news was 44,61EUR and was down -0,04 % compared with the previous day.
13 minutes after the article was published, the price was 44,58EUR this corresponds to a minus of -0,07 % since publication.
At this time, the index DAX was at 25.100,00PKT (-0,06 %).

Fresenius

+1,54 %

-3,98 %

-4,47 %

-0,63 %

-10,41 %

+51,57 %

+4,24 %

-39,63 %

+2.931,43 %

ISIN:DE000FRE5EN2WKN:FRE5EN

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• 10J
• Max

Fresenius direkt bei SMARTBROKER+ handelnKaufVerkauf

Prämie Jetzt bis zu 120 € Prämie sichern! Egal ob Trading, Sparen oder beides - bei SMARTBROKER+ ist für alle was dabei. Jetzt Depot eröffnen und sichern!

Schreibe Deinen Kommentar